Equities

Evolent Health Inc

Evolent Health Inc

Actions
Health CareHealth Care Providers
  • Price (USD)11.59
  • Today's Change0.28 / 2.48%
  • Shares traded2.99m
  • 1 Year change-59.71%
  • Beta1.5105
Data delayed at least 15 minutes, as of Nov 21 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform10
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Evolent Health Inc have a median target of 23.50, with a high estimate of 47.21 and a low estimate of 16.00. The median estimate represents a 107.78% increase from the last price of 11.31.
High317.4%47.21
Med107.8%23.50
Low41.5%16.00

Earnings history & estimates in USD

On Nov 07, 2024, Evolent Health Inc reported 3rd quarter 2024 earnings of 0.04 per share.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-18.48%
Evolent Health Inc reported annual 2023 earnings of 0.87 per share on Feb 22, 2024.
Average growth rate+1,570.80%
More ▼

Revenue history & estimates in USD

Evolent Health, Inc. had 3rd quarter 2024 revenues of 621.40m. This missed the 627.15m consensus estimate of the 14 analysts following the company. This was 45.29% above the prior year's 3rd quarter results.
Average growth rate+5.26%
Evolent Health, Inc. had revenues for the full year 2023 of 1.96bn. This was 45.26% above the prior year's results.
Average growth rate+25.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.